BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LNS8801 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LNS8801\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06624644-2596@assetmemo.bio
DTSTAMP:20261121T005912Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:LNS8801: Phase 2/3 readout est. (NCT06624644)
DESCRIPTION:LNS8801\, phase 2/3\, Melanoma.\nStudy: A Trial of LNS8801 With
  or Without Pembrolizumab in Patients With Refractory Melanoma\nEstimated 
 primary completion: February 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/lns8801#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06624644
URL:https://assetmemo.bio/drug/lns8801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
